Encorafenib (Braftovi)
Revision as of 17:03, 25 July 2017 by Warner-admin (talk | contribs) (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications")
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.